Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+)
Stratifies risk for patients with overt primary myelofibrosis (PMF).
INSTRUCTIONS
Be aware, this tool provides results for either MIPSS70 or MIPSS70+, version 2.0, depending on whether karyotype information is available.
- If karyotype is not available, this tool will default to MIPSS70.
- If karyotype information is inputted, the tool will default to MIPSS70+. which will also affect hemoglobin (i.e., more specific anemia cutoff values) and HMR mutation inputs (i.e., the inclusion of U2AR1 Q157).
Result:
Please fill out required fields.
Dr. Paola Guglielmelli
About the creator
Paola Guglielmelli, MD, is a researcher scientist in hematology at the University of Florence. She is a member of CRIMM and has contributed extensively to understanding the molecular and epigenetic mechanisms in myeloproliferative neoplasms (MPN). Dr. Guglielmelli is a distinguished researcher studying the JAK-STAT pathway, Calreticulin, and PI3K/Akt/mTOR pathways, with a focus on developing novel therapeutic strategies for MPN.
To view Dr. Paola Guglielmelli's publications, visit PubMed
Are you Dr. Paola Guglielmelli? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.